论文部分内容阅读
目的探讨表皮生长因子受体酪氨酸激酶抑制剂吉非替尼治疗晚期非小细胞肺癌(NSCLC)长期生存的影响因素。方法分析2002年12月～2006年4月北京协和医院204例晚期NSCLC患者经吉非替尼250mg/日口服治疗的3年生存情况。应用x~2检验进行统计分析。结果吉非替尼长期生存优于化疗,3年生存率16.2%。吸烟史(P= 0.043)、治疗疗效(P=0.002)和病理类型(P=0.011)是与吉非替尼治疗生存时间密切相关的因素,而性别(P=0.762)、年龄(P=0.053)、ECOG评分(P=0.380)、既往治疗方法(P=0.222)及临床分期(P=0.135)则与之无显著关系。结论吉非替尼是1种有效的治疗NSCLC的靶向药物,可以改善NSCLC患者的生存时间。根据患者具体情况选择合适肺癌患者并进行吉非替尼治疗可望使肺癌治疗更为个体化,具有更好的临床应用前景。
Objective To investigate the factors affecting the long-term survival of advanced non-small cell lung cancer (NSCLC) treated with epidermal growth factor receptor tyrosine kinase inhibitor gefitinib. Methods Three-year survival rates of 204 patients with advanced non-small cell lung cancer (NSCLC) treated with gefitinib 250 mg / day orally from December 2002 to April 2006 in Peking Union Medical College Hospital were analyzed. Apply x ~ 2 test for statistical analysis. Results The long-term survival of gefitinib was superior to chemotherapy, and the 3-year survival rate was 16.2%. The smoking history (P = 0.043), treatment effect (P = 0.002) and pathological type (P = 0.011) were closely related to the survival time of gefitinib, ), ECOG score (P = 0.380), previous treatment (P = 0.222) and clinical stage (P = 0.135) had no significant relationship. Conclusion Gefitinib is an effective drug for the treatment of NSCLC and can improve the survival time of patients with NSCLC. According to the specific circumstances of patients select the appropriate lung cancer patients and treatment of gefitinib is expected to make the treatment of lung cancer more individualized, with better clinical application prospects.